Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C15H10F3N3O4S2 and a molecular weight of approximately 417.4 g/mol[6]. It contains a thiazolidinone core linked to a furan ring and substituted with both sulfonamide and trifluoromethyl groups. The compound is catalogued in chemical databases such as PubChem (CID: 137349068), ChEMBL (CHEMBL233970), and DrugBank (DB07538)[6]. There are no approved medical indications or clinical trials associated with this molecule as of now[8]. Its mechanism of action, biological targets, pharmacological activity, or therapeutic potential have not been established in the literature or major drug databases[8][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-{5-[(Z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}-2-(trifluoromethyl)benzenesulfonamide.